StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The significant trial results likely boost investor confidence, similar to past positive drug trials driving similar stocks higher.
What happened, with direct paths to the underlying reporting
Candel's CAN-2409 trial met primary endpoint for prostate cancer treatment. Significant disease-free survival improvement observed with CAN-2409 plus standard care. CAN-2409 showed 67.1% PSA nadir achievement vs. 58.6% in control group. Safety profile consistent, with mild adverse events noted. CADL stock rose 167.70% to $12.34 in premarket trading.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.